BRPI0509587A - processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter - Google Patents

processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter

Info

Publication number
BRPI0509587A
BRPI0509587A BRPI0509587-5A BRPI0509587A BRPI0509587A BR PI0509587 A BRPI0509587 A BR PI0509587A BR PI0509587 A BRPI0509587 A BR PI0509587A BR PI0509587 A BRPI0509587 A BR PI0509587A
Authority
BR
Brazil
Prior art keywords
composition
preparing
boronic ester
ether solvent
aminoboronic
Prior art date
Application number
BRPI0509587-5A
Other languages
English (en)
Inventor
I Fraser Pickersgill
John Bishop
Christoph Koellner
Jean-Marc Gomez
Achim Geiser
Robert Hett
Vince Ammoscato
Stephen Munk
Young Lo
Fang-Ting Chui
Vithalanand R Kulkarni
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509587(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BRPI0509587A publication Critical patent/BRPI0509587A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PROCESSO EM GRANDE ESCALA PARA PREPARAR UM COMPOSTO DE éSTER BORÈNICO, AMINOBORÈNICO E COMPOSIçãO QUE COMPREENDE UM SOLVENTE DE éTER. A invenção refere-se à síntese de compostos de ácido e de éster borónico. Mais particularmente, a invenção proporciona processos sintéticos aper- feiçoados adequados para a produção em grande escala de compostos de ácido e de éster borónico, incluindo o bortezomib inibidor de protéassoma de ácido borónico peptídico.
BRPI0509587-5A 2004-03-30 2005-03-24 processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter BRPI0509587A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30
PCT/US2005/009774 WO2005097809A2 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds

Publications (1)

Publication Number Publication Date
BRPI0509587A true BRPI0509587A (pt) 2007-09-25

Family

ID=34968044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509587-5A BRPI0509587A (pt) 2004-03-30 2005-03-24 processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter

Country Status (41)

Country Link
US (14) US7714159B2 (pt)
EP (5) EP3385267B1 (pt)
JP (4) JP4558039B2 (pt)
KR (1) KR100939598B1 (pt)
CN (5) CN103396427B (pt)
AR (3) AR049374A1 (pt)
AT (1) ATE521612T1 (pt)
AU (1) AU2005230930B2 (pt)
BR (1) BRPI0509587A (pt)
CA (4) CA2738706C (pt)
CL (2) CL2010000350A1 (pt)
CR (1) CR8653A (pt)
CY (3) CY1112053T1 (pt)
DK (4) DK4008721T3 (pt)
DO (1) DOP2011000293A (pt)
EA (1) EA012927B1 (pt)
EC (1) ECSP066960A (pt)
ES (3) ES2457593T3 (pt)
FI (1) FI4008721T3 (pt)
HK (4) HK1100004A1 (pt)
HR (4) HRP20212002T1 (pt)
HU (1) HUE056859T2 (pt)
IL (3) IL178250A (pt)
LT (2) LT4008721T (pt)
ME (1) ME01975B (pt)
MX (1) MX367324B (pt)
MY (1) MY145427A (pt)
NL (3) NL1028639C2 (pt)
NO (4) NO338905B1 (pt)
NZ (3) NZ550522A (pt)
PE (3) PE20142402A1 (pt)
PL (4) PL3385267T3 (pt)
PT (4) PT4008721T (pt)
RS (4) RS65253B1 (pt)
SG (5) SG151322A1 (pt)
SI (3) SI1756121T1 (pt)
TW (1) TWI386212B (pt)
UA (1) UA90108C2 (pt)
UY (3) UY28830A1 (pt)
WO (1) WO2005097809A2 (pt)
ZA (1) ZA200608689B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
RS65253B1 (sr) 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20160040735A (ko) * 2007-08-06 2016-04-14 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
MX2010002836A (es) * 2007-09-12 2010-03-31 Reddys Lab Ltd Dr Bortezomib y proceso para la produccion del mismo.
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA027346B1 (ru) 2008-06-17 2017-07-31 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
AU2013204889A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2516449A1 (en) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011098963A1 (en) 2010-02-09 2011-08-18 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
CN107266485A (zh) 2010-03-31 2017-10-20 米伦纽姆医药公司 1‑氨基‑2‑环丙基乙硼酸衍生物
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
EP2723751A1 (en) 2011-06-22 2014-04-30 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
BR112014015363A2 (pt) * 2011-12-22 2017-06-13 Ares Trading Sa derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
KR20150067175A (ko) * 2012-09-11 2015-06-17 시플라 리미티드 보르테조밉을 제조하기 위한 방법
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
AU2013346322B2 (en) 2012-11-16 2016-11-10 Shilpa Medicare Limited Crystalline Bortezomib process
EP2928898B1 (en) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
IN2013MU01431A (pt) 2013-04-16 2015-06-26 Cipla Ltd
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
WO2015117136A1 (en) 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
NZ725948A (en) 2014-05-20 2024-01-26 Takeda Pharmaceuticals Co Boron-containing proteasome inhibitors for use after primary cancer therapy
EP3154989B1 (en) 2014-06-11 2021-03-24 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
CN110312727A (zh) * 2017-02-17 2019-10-08 费森尤斯卡比肿瘤学有限公司 一种改进的制备硼酸酯的方法
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
WO2019043544A1 (en) * 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
PT1355910E (pt) * 2001-01-25 2011-03-24 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulação de compostos do ácido borónico
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP2012530116A (ja) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法

Also Published As

Publication number Publication date
PE20110075A1 (es) 2011-02-17
KR20070007873A (ko) 2007-01-16
WO2005097809A2 (en) 2005-10-20
US9862745B2 (en) 2018-01-09
SI2377869T1 (sl) 2014-05-30
FI4008721T3 (fi) 2024-03-19
HK1164320A1 (en) 2012-10-19
TWI386212B (zh) 2013-02-21
EP2377868A1 (en) 2011-10-19
AR097309A2 (es) 2016-03-02
IL219853A (en) 2015-05-31
HUE056859T2 (hu) 2022-03-28
SG182999A1 (en) 2012-08-30
DOP2011000293A (es) 2011-12-15
ATE521612T1 (de) 2011-09-15
EP4008721A1 (en) 2022-06-08
TW200616646A (en) 2006-06-01
NO338905B1 (no) 2016-10-31
NZ550522A (en) 2010-08-27
EA200601795A1 (ru) 2007-04-27
CA2560886A1 (en) 2005-10-20
UY28830A1 (es) 2005-09-30
NL1028639A1 (nl) 2005-10-20
AU2005230930A1 (en) 2005-10-20
US20180265546A1 (en) 2018-09-20
RS62738B1 (sr) 2022-01-31
HRP20140339T1 (hr) 2014-05-09
HRP20212002T1 (hr) 2022-04-01
ECSP066960A (es) 2006-12-20
CN111925385B (zh) 2023-11-21
NZ586824A (en) 2012-03-30
SG10201600029PA (en) 2016-02-26
CN108329337A (zh) 2018-07-27
SG151322A1 (en) 2009-04-30
JP2016056180A (ja) 2016-04-21
EP1756121A2 (en) 2007-02-28
SI3385267T1 (sl) 2022-04-29
UY34969A (es) 2015-02-27
IL219856A (en) 2015-05-31
UA90108C2 (uk) 2010-04-12
NO343966B1 (no) 2019-07-29
HK1246300A1 (zh) 2018-09-07
EP3385267A1 (en) 2018-10-10
CN111925385A (zh) 2020-11-13
JP2013100378A (ja) 2013-05-23
PE20060162A1 (es) 2006-04-07
RS65253B1 (sr) 2024-03-29
AR097310A2 (es) 2016-03-02
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
JP2007530687A (ja) 2007-11-01
US20100174072A1 (en) 2010-07-08
EP4008721B1 (en) 2024-01-03
US20160362449A1 (en) 2016-12-15
US20150038706A1 (en) 2015-02-05
NO20064893L (no) 2006-12-22
SG10201800972PA (en) 2018-03-28
LT4008721T (lt) 2024-03-25
MY145427A (en) 2012-02-15
US20210171574A1 (en) 2021-06-10
ZA200608689B (en) 2007-09-26
NL1033190C2 (nl) 2007-11-27
ES2899606T3 (es) 2022-03-14
WO2005097809A3 (en) 2006-02-16
NL1033189C2 (nl) 2008-08-14
HK1257298A1 (zh) 2019-10-18
JP4558039B2 (ja) 2010-10-06
AR049374A1 (es) 2006-07-26
CN1960996B (zh) 2016-04-20
US20050240047A1 (en) 2005-10-27
IL219856A0 (en) 2012-06-28
MX367324B (es) 2019-08-15
US20180044377A1 (en) 2018-02-15
SG182998A1 (en) 2012-08-30
CY1112053T1 (el) 2015-11-04
EP2377869A1 (en) 2011-10-19
AU2005230930B2 (en) 2011-09-29
DK3385267T3 (da) 2021-11-01
US10000529B2 (en) 2018-06-19
US20190330270A1 (en) 2019-10-31
EA012927B1 (ru) 2010-02-26
US8283467B2 (en) 2012-10-09
PE20142402A1 (es) 2015-02-04
ME01975B (me) 2015-05-20
CA2738706C (en) 2014-10-14
PL1756121T3 (pl) 2012-02-29
NO344610B1 (no) 2020-02-10
JP6193960B2 (ja) 2017-09-06
US20210395301A1 (en) 2021-12-23
CN107474062A (zh) 2017-12-15
DK1756121T3 (da) 2012-01-09
US20220204558A1 (en) 2022-06-30
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
PL4008721T3 (pl) 2024-05-13
PL2377869T3 (pl) 2014-07-31
NO20191065A1 (no) 2006-12-22
PT4008721T (pt) 2024-03-21
JP5414625B2 (ja) 2014-02-12
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
IL178250A0 (en) 2006-12-31
KR100939598B1 (ko) 2010-02-01
UY35578A (es) 2016-01-08
CA2738706A1 (en) 2005-10-20
PL3385267T3 (pl) 2022-02-14
CN108329337B (zh) 2021-06-25
PT1756121E (pt) 2011-11-30
NL1033190A1 (nl) 2007-04-23
CA2859119A1 (en) 2005-10-20
DK2377869T3 (da) 2014-04-14
NO20161350A1 (no) 2006-12-22
DK4008721T3 (da) 2024-03-25
HK1100004A1 (en) 2007-08-31
US20190112334A1 (en) 2019-04-18
HRP20240307T3 (hr) 2024-05-10
NZ598172A (en) 2013-08-30
CL2014002252A1 (es) 2014-12-05
US7714159B2 (en) 2010-05-11
RS53259B (en) 2014-08-29
SI1756121T1 (sl) 2012-03-30
PT3385267T (pt) 2021-11-23
EP1756121B1 (en) 2011-08-24
CL2010000350A1 (es) 2011-01-28
CA2560886C (en) 2014-08-12
CN103396427B (zh) 2018-04-13
US20200369722A1 (en) 2020-11-26
JP5894952B2 (ja) 2016-03-30
PT2377869E (pt) 2014-04-15
EP2377869B1 (en) 2014-01-29
EP3385267B1 (en) 2021-09-29
CY1115336T1 (el) 2017-01-04
NO20171939A1 (no) 2006-12-22
JP2010241816A (ja) 2010-10-28
HRP20110846T1 (hr) 2011-12-31
US20200157143A1 (en) 2020-05-21
CN1960996A (zh) 2007-05-09
CY1124753T1 (el) 2022-07-22
ES2371652T3 (es) 2012-01-05
IL219853A0 (en) 2012-06-28
ES2457593T3 (es) 2014-04-28
LT3385267T (lt) 2021-11-10
NL1033189A1 (nl) 2007-10-22

Similar Documents

Publication Publication Date Title
BRPI0509587A (pt) processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
BRPI0500393B8 (pt) forma cristalina ii de agomelatina e sua composição farmacêutica
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
AR074637A1 (es) Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
AR054533A1 (es) Proceso y reactivo magnetico para la separacion de impurezas de los minerales
DE502006009282D1 (de) Verfahren zur substitution von indenofluorenen
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
BR112012018625A2 (pt) archimica
GT200500311A (es) Compuestos organicos
ATE504558T1 (de) Asymmetrische carbonylalkylierung
HRP20120031T1 (hr) Postupak kemijskog spajanja sa derivatom fenil boronske kiseline
AR051386A1 (es) Proceso para compuestos triciclicos que contienen atomos heterogeneos
GT200600102A (es) Procedimiento para la preparacion de compuestos benzoxazol sustituidos
ECSP014080A (es) Un compuesto para preparar compuestos de bifenilo
BRPI0514313A (pt) processo para sintetizar um composto, e, composto
MA32698B1 (fr) Procede de preparation du 1,6:2,3-dianhydro-beta-d-mannopyranose
AR052865A1 (es) Preparacion de compuestos farmaceuticos derivados de sales de piperazina
BRPI0702769A (pt) compostos de naftaleno, processo para sua preparação e composições farmacêuticas contendo os mesmos
BRPI0606861A2 (pt) processo para a produção de anilinas
AR064271A1 (es) Un proceso para la sintesis de solifenacina
TH112949A (th) กรรมวิธีสำหรับการผลิต 1,2-ไดคลอโรอีเทนและสารประกอบอนุพันธ์เอทิลีนอย่างน้อย 1 ชนิดที่แตกต่างจาก 1,2-ไดคลอโรอีเทน

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]